Quality of life in patients with psoriasis: a systematic literature review.

PubWeight™: 1.95‹?› | Rank: Top 2%

🔗 View Article (PMID 15083781)

Published in J Investig Dermatol Symp Proc on March 01, 2004

Authors

John de Korte1, Mirjam A Sprangers, Femke M Mombers, Jan D Bos

Author Affiliations

1: Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. j.dekorte@amc.uva.nl

Articles citing this ↘

Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis (2005) 2.61

Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol (2010) 2.37

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol (2014) 1.57

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis (2012) 1.24

The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes (2009) 1.07

Psoriasis and its management. BMJ (2006) 1.05

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC Med (2012) 1.03

Association between anemia and quality of life in a population sample of individuals with chronic obstructive pulmonary disease. BMC Pulm Med (2006) 0.95

Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence (2013) 0.91

Sleep loss and cytokines levels in an experimental model of psoriasis. PLoS One (2012) 0.91

'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Fam Pract (2013) 0.90

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]. BMC Dermatol (2005) 0.88

Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ (2014) 0.88

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. Adv Ther (2015) 0.87

A Cross-sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis. Indian J Psychol Med (2015) 0.83

Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis. Clin Cosmet Investig Dermatol (2013) 0.82

Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatol Alergol (2014) 0.82

Optimism as a predictor of health-related quality of life in psoriatics. Postepy Dermatol Alergol (2013) 0.80

Lifting the silver flakes: the pathogenesis and management of chronic plaque psoriasis. Biomed Res Int (2013) 0.80

A study of psoriasis and quality of life in a tertiary care teaching hospital of kottayam, kerala. Indian J Dermatol (2011) 0.79

Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature. Biologics (2009) 0.79

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire. Health Qual Life Outcomes (2012) 0.78

Quality of life in psoriatic patients: a study using the short form-36. Int J Prev Med (2014) 0.78

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment. PLoS One (2015) 0.78

[Comparative psychological aspects of itching and pain]. Schmerz (2011) 0.78

Quality of life and severity of skin changes in the dynamics of psoriasis. Postepy Dermatol Alergol (2016) 0.77

Treatment Satisfaction Among Patients with Moderate-to-severe Psoriasis. J Clin Aesthet Dermatol (2015) 0.77

Psoriasis Patients' Knowledge about the Disease and Treatments. Dermatol Res Pract (2013) 0.77

'I should have taken that further' - missed opportunities during cardiovascular risk assessment in patients with psoriasis in UK primary care settings: a mixed-methods study. Health Expect (2015) 0.77

Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence (2015) 0.76

Update of the management of chronic psoriasis: new approaches and emerging treatment options. Clin Cosmet Investig Dermatol (2010) 0.76

An analysis of dermatological quality-of-life scores in relation to psychiatric morbidity in psoriasis. Indian Dermatol Online J (2016) 0.76

The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis. J Clin Aesthet Dermatol (2016) 0.75

Psoriasis (chronic plaque). BMJ Clin Evid (2009) 0.75

Body Image Disturbance in Acromegaly Patients Compared to Nonfunctioning Pituitary Adenoma Patients and Controls. Int J Endocrinol (2015) 0.75

Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study. An Bras Dermatol (2017) 0.75

Disease Severity, Quality of Life, and Psychiatric Morbidity in Patients With Psoriasis With Reference to Sociodemographic, Lifestyle, and Clinical Variables: A Prospective, Cross-Sectional Study From Lahore, Pakistan. Prim Care Companion CNS Disord (2015) 0.75

Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum (2010) 0.75

Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. J Eur Acad Dermatol Venereol (2016) 0.75

The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives. Am Health Drug Benefits (2016) 0.75

The Relationship between Disease, Work and Sickness Absence among Psoriasis Patients. Iran J Public Health (2015) 0.75

Assessment of the Therapeutic Aspect of Systemic Non-Biologic Anti-Psoriatic Treatment Modalities Used in Combination with Methotrexate. Indian J Dermatol (2016) 0.75

Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. Clinicoecon Outcomes Res (2017) 0.75

Emotion Regulation in Patients with Psoriasis: Correlates of Disability, Clinical Dimensions, and Psychopathology Symptoms. Int J Behav Med (2016) 0.75

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res (2017) 0.75

Articles by these authors ⇆

Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol (2011) 3.68

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Clinical factors associated with quality of life in patients with transient loss of consciousness. J Cardiovasc Electrophysiol (2006) 1.51

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: an international multicenter study. J Clin Oncol (2004) 1.17

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Factors associated with posttraumatic stress symptoms in a prospective cohort of patients after abdominal sepsis: a nomogram. Intensive Care Med (2008) 1.07

Overview of psoriasis. Dermatol Ther (2004) 1.04

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Long-term prevalence of post-traumatic stress disorder symptoms in patients after secondary peritonitis. Crit Care (2007) 0.92

Functional and medical outcomes after tailored surgery for pain due to chronic pancreatitis. Ann Surg (2012) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.90

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Responsiveness: a reinvention of the wheel? Health Qual Life Outcomes (2005) 0.90

Quality of life within one year following presentation after transient loss of consciousness. Am J Cardiol (2007) 0.89

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

Quality of life in bile duct injury patients. Ann Surg (2007) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Explaining change over time in quality of life of adult patients with anorectal malformations or Hirschsprung's disease. Dis Colon Rectum (2006) 0.85

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82

Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82

Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82

Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82

Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82

Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81

Health related quality of life six months following surgical treatment for secondary peritonitis--using the EQ-5D questionnaire. Health Qual Life Outcomes (2007) 0.81

Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol (2003) 0.81

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80

Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80

Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79

Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79

Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79

Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol (2010) 0.78

Characteristics of patients with universal vitiligo and health-related quality of life. Arch Dermatol (2008) 0.77

UVB irradiation of normal human skin favors the development of type-2 T-cells in vivo and in primary dermal cell cultures. Photochem Photobiol (2002) 0.77

Increased incidence of hypercoagulability in patients with leg ulcers caused by leukocytoclastic vasculitis. J Am Acad Dermatol (2004) 0.77

Analysis of risk factors in psoriatic patients with methotrexate-induced increases in transaminase levels. Arch Dermatol (2004) 0.77

Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol (2006) 0.77

Reliability, validity and responsiveness of the syncope functional status questionnaire. J Gen Intern Med (2007) 0.77

Filaggrin loss-of-function mutations and atopic dermatitis as risk factors for hand eczema in apprentice nurses: part II of a prospective cohort study. Contact Dermatitis (2013) 0.76

Smallpox: what the dermatologist should know. Skinmed (2004) 0.76

A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology (2012) 0.76

The course of chronic plaque-type psoriasis in placebo groups of randomized controlled studies. Arch Dermatol (2004) 0.76

Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year. J Dermatolog Treat (2007) 0.76

Proliferating prevalence of concepts and controversies in atopic eczema. J Cosmet Dermatol (2004) 0.75

The use of patch tests in determining hypersensitivity to etanercept and infliximab. Arch Dermatol (2008) 0.75

The atopic epidemic and the humidity hypothesis. J Cosmet Dermatol (2004) 0.75

Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol (2010) 0.75

Quality of life and functional outcome after resection of pancreatic cystic neoplasm. Pancreas (2014) 0.75

A pilot study on tertiary teledermatology: feasibility and acceptance of telecommunication among dermatologists. J Telemed Telecare (2010) 0.75

Evaluation of a clinical guideline for the diagnoses of physical and chronic urticaria and angioedema. Acta Derm Venereol (2002) 0.75

Rudi Harold Cormane (1925-1987): a fabulous researcher and clinician. Clin Dermatol (2009) 0.75

Cyclosporin A and methotrexate are equally effective in reducing T cell numbers in psoriatic skin lesions but have no consistent effect on IFN-gamma and IL-4 expression in psoriatic skin in situ. Arch Dermatol Res (2002) 0.75

IL-4 expression by neutrophils in psoriasis lesional skin upon high-dose UVB exposure. Dermatology (2003) 0.75